JP2017530984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530984A5 JP2017530984A5 JP2017518802A JP2017518802A JP2017530984A5 JP 2017530984 A5 JP2017530984 A5 JP 2017530984A5 JP 2017518802 A JP2017518802 A JP 2017518802A JP 2017518802 A JP2017518802 A JP 2017518802A JP 2017530984 A5 JP2017530984 A5 JP 2017530984A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- alkyl
- composition
- group
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*(C)NC(C1CC1)=O Chemical compound C*(C)NC(C1CC1)=O 0.000 description 9
- SMNAXTKCDCNAQG-YCHJVJMSSA-N CC(C)C(/C=C(/C(N(CC1)CC1c1nc(C)cc(C(C)C)c1)=O)\N)=N Chemical compound CC(C)C(/C=C(/C(N(CC1)CC1c1nc(C)cc(C(C)C)c1)=O)\N)=N SMNAXTKCDCNAQG-YCHJVJMSSA-N 0.000 description 1
- IDHXNQZUWRNLSI-OAJVMADHSA-N CC(C)C(/C=C(/C(N(CC1)CC1c1nc(C)cc(C2CCCC2)c1)=O)\N)=N Chemical compound CC(C)C(/C=C(/C(N(CC1)CC1c1nc(C)cc(C2CCCC2)c1)=O)\N)=N IDHXNQZUWRNLSI-OAJVMADHSA-N 0.000 description 1
- WWKQLKZHPMHBSM-UHFFFAOYSA-N CC(C)[n]1nc(cccc2)c2c1 Chemical compound CC(C)[n]1nc(cccc2)c2c1 WWKQLKZHPMHBSM-UHFFFAOYSA-N 0.000 description 1
- MPBYIDFVBMROTH-UHFFFAOYSA-N CC(C)[n]1ncc(c(F)c2)c1cc2Br Chemical compound CC(C)[n]1ncc(c(F)c2)c1cc2Br MPBYIDFVBMROTH-UHFFFAOYSA-N 0.000 description 1
- QYWHLIHVMLNPCM-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2cc(C)cc(C)n2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2cc(C)cc(C)n2)=O)c1 QYWHLIHVMLNPCM-UHFFFAOYSA-N 0.000 description 1
- ISYYMZGUNVIDIJ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3C#N)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3C#N)c2)=O)c1 ISYYMZGUNVIDIJ-UHFFFAOYSA-N 0.000 description 1
- PSJNUJQXRJBICQ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3Cl)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3Cl)c2)=O)c1 PSJNUJQXRJBICQ-UHFFFAOYSA-N 0.000 description 1
- JLUCSGYYDOSGIT-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cccc3)c3Cl)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cccc3)c3Cl)c2)=O)c1 JLUCSGYYDOSGIT-UHFFFAOYSA-N 0.000 description 1
- ADOPLAZEYVDBNR-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cccc3)c3OC)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c(cccc3)c3OC)c2)=O)c1 ADOPLAZEYVDBNR-UHFFFAOYSA-N 0.000 description 1
- NYBLIBCAYAWPIF-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](C(F)F)nc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](C(F)F)nc3)c2)=O)c1 NYBLIBCAYAWPIF-UHFFFAOYSA-N 0.000 description 1
- UWUKMXRNRWPXRV-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](C)cc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](C)cc3)c2)=O)c1 UWUKMXRNRWPXRV-UHFFFAOYSA-N 0.000 description 1
- ZMMWAYLSGNDHBJ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](Cc4ccccc4)nc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[n](Cc4ccccc4)nc3)c2)=O)c1 ZMMWAYLSGNDHBJ-UHFFFAOYSA-N 0.000 description 1
- DKUQJFPELDXTEG-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[o]cc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[o]cc3)c2)=O)c1 DKUQJFPELDXTEG-UHFFFAOYSA-N 0.000 description 1
- AMLCZZBEFOGSRO-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[s]cc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3c[s]cc3)c2)=O)c1 AMLCZZBEFOGSRO-UHFFFAOYSA-N 0.000 description 1
- FHHZGVYBDCHFED-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cccc(C#N)c3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cccc(C#N)c3)c2)=O)c1 FHHZGVYBDCHFED-UHFFFAOYSA-N 0.000 description 1
- ZDEOCJBDKFWTIB-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cccc(Cl)c3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cccc(Cl)c3)c2)=O)c1 ZDEOCJBDKFWTIB-UHFFFAOYSA-N 0.000 description 1
- GYTIXMGHYWYHPM-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3ccccc3C)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3ccccc3C)c2)=O)c1 GYTIXMGHYWYHPM-UHFFFAOYSA-N 0.000 description 1
- JUGFUMWWAFDCJZ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cnc(C)[s]3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cnc(C)[s]3)c2)=O)c1 JUGFUMWWAFDCJZ-UHFFFAOYSA-N 0.000 description 1
- CKMKMCGQKLICGJ-UHFFFAOYSA-N CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cnccc3)c2)=O)c1 Chemical compound CC(C)c1n[nH]c(C(N(CC2)CC2c2nc(C)cc(-c3cnccc3)c2)=O)c1 CKMKMCGQKLICGJ-UHFFFAOYSA-N 0.000 description 1
- JDIJRRHONXUUMY-BIAFCPFJSA-N CC(C)c1n[nH]c([C@@H](N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3OC)c2)[O]=C)c1 Chemical compound CC(C)c1n[nH]c([C@@H](N(CC2)CC2c2nc(C)cc(-c(cc3)ccc3OC)c2)[O]=C)c1 JDIJRRHONXUUMY-BIAFCPFJSA-N 0.000 description 1
- CJNWKQKFHSMHHI-UHFFFAOYSA-N CC(C1CNC1)=O Chemical compound CC(C1CNC1)=O CJNWKQKFHSMHHI-UHFFFAOYSA-N 0.000 description 1
- NGGWJGZAKJHKSZ-UHFFFAOYSA-N CC1C=CC(C(NC)=O)=CC1 Chemical compound CC1C=CC(C(NC)=O)=CC1 NGGWJGZAKJHKSZ-UHFFFAOYSA-N 0.000 description 1
- ZHJJLMNCPIHBRM-UHFFFAOYSA-N CC1C=Cc2n[n](C)cc2C1F Chemical compound CC1C=Cc2n[n](C)cc2C1F ZHJJLMNCPIHBRM-UHFFFAOYSA-N 0.000 description 1
- FJXRIACJPBCMCU-JOAIZHEFSA-O CCN/C=C(\C=[NH2+])/c1cc(C(CC2)CN2C(c2cc(C(C)C)n[nH]2)=O)nc(C)c1 Chemical compound CCN/C=C(\C=[NH2+])/c1cc(C(CC2)CN2C(c2cc(C(C)C)n[nH]2)=O)nc(C)c1 FJXRIACJPBCMCU-JOAIZHEFSA-O 0.000 description 1
- GQJXSYYQPWIJOU-ZNDRMEFZSA-N CCc1cc(C(CC2)CN2C(/C(/N)=C/C(C(C)C)=N)=O)nc(C)c1 Chemical compound CCc1cc(C(CC2)CN2C(/C(/N)=C/C(C(C)C)=N)=O)nc(C)c1 GQJXSYYQPWIJOU-ZNDRMEFZSA-N 0.000 description 1
- YCDDKKGCWDMJKY-SSDOTTSWSA-N CNC(C(C1)=CC=C[C@H]1I)=O Chemical compound CNC(C(C1)=CC=C[C@H]1I)=O YCDDKKGCWDMJKY-SSDOTTSWSA-N 0.000 description 1
- TZAYNGPUOOUEAP-UHFFFAOYSA-N C[n]1nc(C(F)(F)F)c(Br)c1 Chemical compound C[n]1nc(C(F)(F)F)c(Br)c1 TZAYNGPUOOUEAP-UHFFFAOYSA-N 0.000 description 1
- WQYAKZVLTOWKQB-UHFFFAOYSA-N C[n]1ncc(cc2)c1nc2Cl Chemical compound C[n]1ncc(cc2)c1nc2Cl WQYAKZVLTOWKQB-UHFFFAOYSA-N 0.000 description 1
- CSUGQXMRKOKBFI-UHFFFAOYSA-N C[n]1ncc2ccccc12 Chemical compound C[n]1ncc2ccccc12 CSUGQXMRKOKBFI-UHFFFAOYSA-N 0.000 description 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N O=Cc1ccccc1 Chemical compound O=Cc1ccccc1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/088309 | 2014-10-10 | ||
| CN2014088309 | 2014-10-10 | ||
| PCT/US2015/054949 WO2016057924A1 (en) | 2014-10-10 | 2015-10-09 | Pyrrolidine amide compounds as histone demethylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530984A JP2017530984A (ja) | 2017-10-19 |
| JP2017530984A5 true JP2017530984A5 (index.php) | 2018-11-22 |
| JP6783230B2 JP6783230B2 (ja) | 2020-11-11 |
Family
ID=54337935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518802A Expired - Fee Related JP6783230B2 (ja) | 2014-10-10 | 2015-10-09 | ヒストンデメチラーゼのインヒビターとしてのピロリドンアミド化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10022354B2 (index.php) |
| EP (1) | EP3204379B1 (index.php) |
| JP (1) | JP6783230B2 (index.php) |
| CN (1) | CN107912040B (index.php) |
| WO (1) | WO2016057924A1 (index.php) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102017010009A2 (pt) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | Compounds for the treatment of hepatitis b virus infection |
| ES2969239T3 (es) | 2016-05-27 | 2024-05-17 | Gilead Sciences Inc | Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CN117402852A (zh) | 2016-10-14 | 2024-01-16 | 精密生物科学公司 | 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
| TWI714820B (zh) | 2017-01-31 | 2021-01-01 | 美商基利科學股份有限公司 | 替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180008A1 (ar) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| KR20190063745A (ko) * | 2017-11-30 | 2019-06-10 | (주)인핸스드바이오 | p34 단백질 및 NEDD4-1 단백질의 결합 억제제로서의 신규 화합물 및 이의 용도 |
| JP7037667B2 (ja) | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド |
| KR102492115B1 (ko) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드 |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| CN112041311B (zh) | 2018-04-19 | 2023-10-03 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| UA126421C2 (uk) | 2018-07-13 | 2022-09-28 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| AU2019340961B2 (en) * | 2018-09-10 | 2022-07-14 | Shimadzu Corporation | Biological membrane phosphoinositide separation method |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| BR112021008255A2 (pt) | 2018-10-31 | 2021-08-03 | Gilead Sciences, Inc. | compostos de 6-azabenzimidazol substituídos como inibidores de hpk1 |
| CN109852662B (zh) * | 2018-12-25 | 2021-02-19 | 华南农业大学 | 组蛋白甲基化H3K4me3在猪卵巢颗粒细胞中的应用 |
| CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| AU2020231201B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| UA129329C2 (uk) | 2019-06-25 | 2025-03-19 | Гіліад Сайєнсіз, Інк. | ЗЛИТІ БІЛКИ FLT3L-Fc |
| WO2021010492A1 (en) * | 2019-07-17 | 2021-01-21 | Ono Pharmaceutical Co., Ltd. | Compound having kdm5 inhibitory activity and pharmaceutical use thereof |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4037708B1 (en) | 2019-09-30 | 2024-09-18 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| EP4051682A1 (en) * | 2019-10-29 | 2022-09-07 | Biogen MA Inc. | Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| KR102735703B1 (ko) * | 2020-01-29 | 2024-11-28 | 카마리 파마 리미티드 | 피부 장애 치료에서 사용을 위한 화합물 및 조성물 |
| CN111138289B (zh) * | 2020-02-27 | 2022-08-30 | 奥锐特药业(天津)有限公司 | 一种化合物及使用该化合物合成5-乙酰基-1h-吡唑-3-羧酸的工艺 |
| US12552806B2 (en) | 2020-03-20 | 2026-02-17 | University Of Southern California | Androgen receptor regulation by small molecule enantiomers |
| CA3169348A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| BR112022022005A2 (pt) * | 2020-05-07 | 2022-12-13 | Ono Pharmaceutical Co | Derivado de 3-azabiciclo(3.1.0)hexano tendo atividade inibidora da kdm5 e uso do mesmo |
| CR20230071A (es) | 2020-08-07 | 2023-04-11 | Gilead Sciences Inc | Profármacos de análogos de nucleótidos de fosfonamida y su uso farmacéutico |
| US20230391752A1 (en) * | 2020-10-22 | 2023-12-07 | Chulalongkorn University | Pyrrolidine-3-carboxamide derivatives and related uses |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7743829B2 (ja) * | 2021-11-05 | 2025-09-25 | 小野薬品工業株式会社 | Ｋｄｍ５阻害作用を有する化合物を含有する医薬組成物 |
| EP4615431A1 (en) | 2022-11-11 | 2025-09-17 | Astrazeneca AB | Combination therapies for the treatment of cancer |
| CN116284202B (zh) * | 2023-03-28 | 2024-07-02 | 华侨大学 | 白桦脂酸的PROTACs化合物及其制备方法和应用 |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| TW202544019A (zh) | 2024-05-13 | 2025-11-16 | 美商基利科學股份有限公司 | 組合療法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| PT659439E (pt) | 1993-12-24 | 2002-04-29 | Merck Patent Gmbh | Imunoconjugados |
| US5679683A (en) | 1994-01-25 | 1997-10-21 | Warner-Lambert Company | Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| PL179659B1 (pl) | 1994-07-21 | 2000-10-31 | Akzo Nobel Nv | Kompozycja cyklicznych nadtlenków ketonów sluzaca do modyfikowania (ko)polimerów zwlaszcza do degradacji polipropylenu PL PL PL PL PL PL PL |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| PT817775E (pt) | 1995-03-30 | 2002-01-30 | Pfizer | Derivados de quinazolina |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| IL122855A (en) | 1995-07-06 | 2004-08-31 | Novartis Ag | History of N-Phenyl (Alkyl) - 7H-Pyrolo [-3,2d] Pyrimidine - 4 Amine, their preparation and pharmaceutical preparations containing them |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CZ295468B6 (cs) | 1996-04-12 | 2005-08-17 | Warner-Lambert Company | Polycyklické sloučeniny |
| WO1998002434A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| PT980244E (pt) | 1997-05-06 | 2003-10-31 | Wyeth Corp | Utilizacao de compostos de quinazolina para o tratamento da doenca policistica renal |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU1308799A (en) | 1997-11-06 | 1999-05-31 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| NZ512189A (en) | 1998-11-19 | 2003-10-31 | Warner Lambert Co | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4- yl-propoxy)-quinazolin-6-yl]-acrylamide useful as an irreversible inhibitor of tyrosine kinases |
| CA2738563C (en) * | 2008-10-02 | 2014-02-11 | Asahi Kasei Pharma Corporation | 8-substituted isoquinoline derivatives and the use thereof |
| US8513244B2 (en) * | 2011-05-31 | 2013-08-20 | Theravance, Inc. | Neprilysin inhibitors |
| EP2852584B1 (en) * | 2012-05-22 | 2018-02-28 | F. Hoffmann-La Roche AG | Substituted dipyridylamines and uses thereof |
| US9730940B2 (en) * | 2012-11-16 | 2017-08-15 | Merck Sharp & Dohme | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
| EP2968282B1 (en) * | 2013-03-12 | 2018-05-09 | Celgene Quanticel Research, Inc. | Histone dementhylase inhibitors |
| WO2014139326A1 (en) * | 2013-03-13 | 2014-09-18 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
-
2015
- 2015-10-09 CN CN201580066844.9A patent/CN107912040B/zh not_active Expired - Fee Related
- 2015-10-09 JP JP2017518802A patent/JP6783230B2/ja not_active Expired - Fee Related
- 2015-10-09 WO PCT/US2015/054949 patent/WO2016057924A1/en not_active Ceased
- 2015-10-09 EP EP15784257.6A patent/EP3204379B1/en active Active
-
2017
- 2017-04-07 US US15/482,584 patent/US10022354B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530984A5 (index.php) | ||
| JP2018505169A5 (index.php) | ||
| JP2018510851A5 (index.php) | ||
| RU2016110096A (ru) | Новое хинолин-замещенное соединение | |
| JP2017528524A5 (index.php) | ||
| JP2016529312A5 (index.php) | ||
| JP2019510832A5 (index.php) | ||
| JP2017518334A5 (index.php) | ||
| JP2019516759A5 (index.php) | ||
| JP2018525441A5 (index.php) | ||
| RU2013137452A (ru) | Композиции, содержащие расщепляемое ферментами пролекарство оксикодона | |
| JP2016516020A5 (index.php) | ||
| JP2016539134A5 (index.php) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2017101088A (ja) | 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法 | |
| JP2009504764A5 (index.php) | ||
| JP2015500209A5 (index.php) | ||
| JP2015518004A5 (index.php) | ||
| JP2013510123A5 (index.php) | ||
| JP2020506951A5 (index.php) | ||
| JP2017141277A5 (index.php) | ||
| JP2014505107A5 (index.php) | ||
| JP2014511383A5 (index.php) | ||
| JP2016515110A5 (index.php) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения |